Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Amortization of Deferred Charges (2021 - 2025)

Heron Therapeutics filings provide 5 years of Amortization of Deferred Charges readings, the most recent being -$35000.0 for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 166.04% to -$35000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $118000.0, a 61.31% decrease, with the full-year FY2025 number at $73000.0, down 65.24% from a year prior.
  • Amortization of Deferred Charges hit -$35000.0 in Q4 2025 for Heron Therapeutics, down from $100000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $100000.0 in Q3 2023 to a low of -$35000.0 in Q4 2025.
  • Median Amortization of Deferred Charges over the past 5 years was $51000.0 (2022), compared with a mean of $55333.3.
  • Biggest five-year swings in Amortization of Deferred Charges: surged 163.16% in 2022 and later crashed 166.04% in 2025.
  • Heron Therapeutics' Amortization of Deferred Charges stood at $50000.0 in 2021, then changed by 0.0% to $50000.0 in 2022, then rose by 2.0% to $51000.0 in 2023, then grew by 3.92% to $53000.0 in 2024, then crashed by 166.04% to -$35000.0 in 2025.
  • The last three reported values for Amortization of Deferred Charges were -$35000.0 (Q4 2025), $100000.0 (Q2 2025), and $53000.0 (Q1 2025) per Business Quant data.